Emixustat and lampalizumab: Potential therapeutic options for geographic atrophy

Loren S. Jack, Mohammad Ali Sadiq, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.

Original languageEnglish (US)
Pages (from-to)302-309
Number of pages8
JournalDevelopments in Ophthalmology
Volume55
DOIs
StatePublished - Jan 1 2015

Fingerprint

Geographic Atrophy
Macular Degeneration
Complement Factor D
Phase III Clinical Trials
Therapeutics
Clinical Trials
emixustat
lampalizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Emixustat and lampalizumab : Potential therapeutic options for geographic atrophy. / Jack, Loren S.; Sadiq, Mohammad Ali; Do, Diana V.; Nguyen, Quan Dong.

In: Developments in Ophthalmology, Vol. 55, 01.01.2015, p. 302-309.

Research output: Contribution to journalArticle

Jack, Loren S. ; Sadiq, Mohammad Ali ; Do, Diana V. ; Nguyen, Quan Dong. / Emixustat and lampalizumab : Potential therapeutic options for geographic atrophy. In: Developments in Ophthalmology. 2015 ; Vol. 55. pp. 302-309.
@article{138efcd946514a609bd0570b2215e8dc,
title = "Emixustat and lampalizumab: Potential therapeutic options for geographic atrophy",
abstract = "Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.",
author = "Jack, {Loren S.} and Sadiq, {Mohammad Ali} and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2015",
month = "1",
day = "1",
doi = "10.1159/000438954",
language = "English (US)",
volume = "55",
pages = "302--309",
journal = "Developments in Ophthalmology",
issn = "0250-3751",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Emixustat and lampalizumab

T2 - Potential therapeutic options for geographic atrophy

AU - Jack, Loren S.

AU - Sadiq, Mohammad Ali

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.

AB - Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.

UR - http://www.scopus.com/inward/record.url?scp=84947261989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947261989&partnerID=8YFLogxK

U2 - 10.1159/000438954

DO - 10.1159/000438954

M3 - Article

C2 - 26501510

AN - SCOPUS:84947261989

VL - 55

SP - 302

EP - 309

JO - Developments in Ophthalmology

JF - Developments in Ophthalmology

SN - 0250-3751

ER -